121 related articles for article (PubMed ID: 19808073)
1. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
[TBL] [Abstract][Full Text] [Related]
2. Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.
Onoue S; Misaka S; Aoki Y; Karaki S; Kuwahara A; Ohide A; Mizumoto T; Yamada S
Eur J Pharm Sci; 2010 Nov; 41(3-4):508-14. PubMed ID: 20797433
[TBL] [Abstract][Full Text] [Related]
3. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
[TBL] [Abstract][Full Text] [Related]
4. Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.
Onoue S; Matsui T; Kato M; Mizumoto T; Liu B; Liu L; Karaki S; Kuwahara A; Yamada S
Eur J Pharm Sci; 2013 Jun; 49(3):382-9. PubMed ID: 23608612
[TBL] [Abstract][Full Text] [Related]
5. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.
Onoue S; Matsui T; Kuriyama K; Ogawa K; Kojo Y; Mizumoto T; Karaki S; Kuwahara A; Yamada S
Peptides; 2012 Jun; 35(2):182-9. PubMed ID: 22484228
[TBL] [Abstract][Full Text] [Related]
6. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
[TBL] [Abstract][Full Text] [Related]
7. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532).
Ohmori Y; Maruyama S; Kimura R; Onoue S; Matsumoto A; Endo K; Iwanaga T; Kashimoto K; Yamada S
Regul Pept; 2004 Dec; 123(1-3):201-7. PubMed ID: 15518913
[TBL] [Abstract][Full Text] [Related]
9. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
Onoue S; Yamada S; Yajima T
Peptides; 2007 Sep; 28(9):1640-50. PubMed ID: 17537541
[TBL] [Abstract][Full Text] [Related]
10. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.
Misaka S; Sato H; Yamauchi Y; Onoue S; Yamada S
Eur J Pharm Sci; 2009 Jun; 37(3-4):469-76. PubMed ID: 19491038
[TBL] [Abstract][Full Text] [Related]
11. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S
Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931
[TBL] [Abstract][Full Text] [Related]
12. Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis.
Misaka S; Sato H; Aoki Y; Mizumoto T; Onoue S; Yamada S
Peptides; 2011 Feb; 32(2):401-7. PubMed ID: 20977915
[TBL] [Abstract][Full Text] [Related]
13. Respirable powder formulation of a shortened vasoactive intestinal peptide analog for treatment of airway inflammatory diseases.
Suzuki H; Mizumoto T; Seto Y; Sato H; Onoue S
J Pept Sci; 2018 Mar; 24(3):. PubMed ID: 29441631
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte function in the airways of allergen-challenged pigs: effects of inhaled and systemic budesonide.
Fornhem C; Peterson CG; Dahlbäck M; Scheynius A; Alving K
Clin Exp Allergy; 1996 Dec; 26(12):1436-48. PubMed ID: 9027445
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.
Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S
J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169
[TBL] [Abstract][Full Text] [Related]
16. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
Onoue S; Sato H; Ogawa K; Kojo Y; Aoki Y; Kawabata Y; Wada K; Mizumoto T; Yamada S
Eur J Pharm Biopharm; 2012 Jan; 80(1):54-60. PubMed ID: 22008148
[TBL] [Abstract][Full Text] [Related]
17. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.
Onoue S; Aoki Y; Kawabata Y; Matsui T; Yamamoto K; Sato H; Yamauchi Y; Yamada S
J Pharm Sci; 2011 Feb; 100(2):622-33. PubMed ID: 20653048
[TBL] [Abstract][Full Text] [Related]
18. Inhalable liposomal formulation for vasoactive intestinal peptide.
Hajos F; Stark B; Hensler S; Prassl R; Mosgoeller W
Int J Pharm; 2008 Jun; 357(1-2):286-94. PubMed ID: 18328650
[TBL] [Abstract][Full Text] [Related]
19. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
Stark B; Andreae F; Mosgoeller W; Edetsberger M; Gaubitzer E; Koehler G; Prassl R
Eur J Pharm Biopharm; 2008 Sep; 70(1):153-64. PubMed ID: 18555674
[TBL] [Abstract][Full Text] [Related]
20. Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.
Seto Y; Suzuki G; Leung SS; Chan HK; Onoue S
Pharm Res; 2016 Jun; 33(6):1447-55. PubMed ID: 26975360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
